Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        111-120 of 217 results for 'impetigo'

        Refine search

        Research

        CASSETTE-clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation: Study protocol for a randomised controlled trial

        This study will assess the effect of adjunctive clindamycin on patient-centred outcomes in severe, toxin-mediated S. aureus infections ...

        Research

        Pre-exposure prophylaxis for HIV prevention during pregnancy and lactation: forget not the women and children

        The framework for appropriately identifying and managing at-risk pregnant and lactating women requiring PrEP is poorly defined ...

        Research

        SNAP-Chat: the Staphylococcus aureus Network Adaptive Platform Trial (SNAP) - Chat

        Dr Anita Asha Campbell Bowen AC AC MBBS, DCH, PG DipPID, FRACP, NHMRC Postgraduate Scholarship BA MBBS DCH FRACP PhD GAICD OAM Infectious Diseases ...

        News & Events

        Telethon Kids researchers finalists in Premier’s Science Awards

        Telethon Kids Institute has two researchers and an innovative science engagement initiative as finalists in the 2017 Premier’s Science Awards. ...

        Research

        Population pharmacokinetic study of benzathine penicillin G administration in Indigenous children and young adults with rheumatic heart disease in the Northern Territory, Australia

        Benzathine penicillin G is the cornerstone of secondary prophylaxis to prevent Streptococcus pyogenes infections, which precede acute rheumatic fever. ...

        News & Events

        Major funding aims to improve skin cancer outcomes for young Aboriginal people

        Vital research promoting sun smart choices and skin cancer prevention for young Aboriginal people is now underway at Telethon Kids Institute thanks to a $100,000 Perpetual 2024 IMPACT Philanthropy grant. ...

        Research

        Consumer perspectives on simplified, layered consent for a low risk, but complex pragmatic trial

        For decades, the research community has called for participant information sheets/consent forms (PICFs) to be improved. Recommendations include simplifying content, reducing length, presenting information in layers and using multimedia. However, there are relatively few studies that have evaluated health consumers' (patients/carers) perspectives on the type and organisation of information, and the level of detail to be included in a PICF to optimise an informed decision to enter a trial. ...

        Research

        A model of population dynamics with complex household structure and mobility: implications for transmission and control of communicable diseases

        Households are known to be high-risk locations for the transmission of communicable diseases. Numerous modelling studies have demonstrated the important role of households in sustaining both communicable diseases outbreaks and endemic transmission, and as the focus for control efforts. However, these studies typically assume that households are associated with a single dwelling and have static membership. ...

        Research

        A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial

        The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is a multifactorial Bayesian adaptive platform trial that aims to improve the way that S. aureus bloodstream infection, a globally common and severe infectious disease, is treated. In a world first, the SNAP trial will simultaneously investigate the effects of multiple intervention modalities within multiple groups of participants with different forms of S. aureus bloodstream infection. ...

        Research

        The Staphylococcus aureus Network Adaptive Platform Trial Protocol: New Tools for an Old Foe

        Staphylococcus aureus bloodstream (SAB) infection is a common and severe infectious disease, with a 90-day mortality of 15%-30%. Despite this, <3000 people have been randomized into clinical trials of treatments for SAB infection. ...

        Page 12 of 22